Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:LIMN NASDAQ:ORKA NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.35-5.3%$7.30$5.90▼$30.31$536.48M2.171.50 million shs1.54 million shsLIMNLiminatus Pharma$5.42-0.9%$0.00$4.40▼$33.66$142.30MN/A352,495 shs263,480 shsORKAOruka Therapeutics$14.54-5.3%$12.07$5.49▼$31.13$544.39M-0.34234,544 shs389,758 shsRAPPRapport Therapeutics$14.68-1.1%$11.68$6.43▼$29.74$541.63MN/A166,324 shs137,409 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-5.28%-5.65%-1.61%-14.53%-76.43%LIMNLiminatus Pharma-0.91%-18.50%+541,999,900.00%+541,999,900.00%+541,999,900.00%ORKAOruka Therapeutics-5.34%+2.18%+21.37%+57.79%+1,453,999,900.00%RAPPRapport Therapeutics-1.08%+0.55%+33.09%+44.63%-43.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas3.8851 of 5 stars4.34.00.00.01.82.51.3LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/AORKAOruka Therapeutics2.873 of 5 stars3.60.00.00.02.62.50.6RAPPRapport Therapeutics1.3142 of 5 stars3.50.00.00.01.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$20.29176.05% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/AORKAOruka Therapeutics 3.20Buy$40.38177.68% UpsideRAPPRapport Therapeutics 3.00Buy$28.0090.74% UpsideCurrent Analyst Ratings BreakdownLatest LIMN, RAPP, ORKA, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.006/2/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.006/2/2025ARVNArvinasLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.006/1/2025ARVNArvinasLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$426.90M1.26N/AN/A$8.17 per share0.90LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%7/30/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)Latest LIMN, RAPP, ORKA, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RAPPRapport Therapeutics-$0.87N/AN/AN/AN/AN/A8/7/2025Q1 2025ORKAOruka Therapeutics-$0.48N/AN/AN/AN/AN/A7/29/2025Q2 2025ARVNArvinas-$0.87N/AN/AN/A$34.42 millionN/A5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.584.58LIMNLiminatus PharmaN/AN/AN/AORKAOruka TherapeuticsN/A30.0330.03RAPPRapport TherapeuticsN/A31.0131.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%LIMNLiminatus PharmaN/AORKAOruka Therapeutics56.44%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas4.73%LIMNLiminatus PharmaN/AORKAOruka Therapeutics24.69%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42072.99 million69.54 millionOptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/AORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ARAPPRapport TherapeuticsN/A36.50 millionN/AN/ALIMN, RAPP, ORKA, and ARVN HeadlinesRecent News About These CompaniesRapport Therapeutics, Inc. (NASDAQ:RAPP) Insider Sells $119,000.00 in StockJuly 16 at 7:18 PM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 5.3% - Time to Buy?July 16 at 1:00 PM | marketbeat.comAI therapy bots fuel delusions and give dangerous advice, Stanford study findsJuly 11, 2025 | arstechnica.comARapport Therapeutics (NASDAQ:RAPP) Shares Down 6.3% - Should You Sell?July 11, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 9.8% Higher - Here's WhyJuly 9, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Receives "Market Outperform" Rating from JMP SecuritiesJuly 8, 2025 | marketbeat.comRapport Therapeutics stock rating reiterated as Buy by TD CowenJuly 2, 2025 | uk.investing.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)...June 12, 2025 | marketbeat.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comRapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 16, 2025 | finance.yahoo.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comInductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI PlatformMay 7, 2025 | finance.yahoo.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%May 3, 2025 | aaii.comAMise à disposition du rapport financier annuel 2024April 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIMN, RAPP, ORKA, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$7.35 -0.41 (-5.28%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.40 +0.05 (+0.68%) As of 07/18/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Liminatus Pharma NASDAQ:LIMN$5.42 -0.05 (-0.91%) As of 07/18/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Oruka Therapeutics NASDAQ:ORKA$14.54 -0.82 (-5.34%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.54 +0.01 (+0.03%) As of 07/18/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Rapport Therapeutics NASDAQ:RAPP$14.68 -0.16 (-1.08%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.70 +0.03 (+0.17%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
